The New Paper

December 14, 2020

AstraZeneca announces $39B acquisition of Alexion

AstraZeneca announced plans to acquire US-based Alexion Pharmaceuticals for $39B on Saturday. Alexion is an immunology-focused pharmaceutical company that focuses on drug development for rare diseases. If completed, the deal would be the largest acquisition in AstraZeneca’s history and among the largest transactions of the year.
This story is from the December 14, 2020 edition of The New Paper – a clear, concise daily briefing that makes fact-first news easy to consume. Try it today.